000292074 001__ 292074
000292074 005__ 20250731110849.0
000292074 0247_ $$2doi$$a10.1002/ijc.35114
000292074 0247_ $$2pmid$$apmid:39057841
000292074 0247_ $$2ISSN$$a0020-7136
000292074 0247_ $$2ISSN$$a1097-0215
000292074 0247_ $$2altmetric$$aaltmetric:165755066
000292074 037__ $$aDKFZ-2024-01582
000292074 041__ $$aEnglish
000292074 082__ $$a610
000292074 1001_ $$00000-0003-0082-7393$$aLi, Jinze$$b0
000292074 245__ $$aPre-diagnostic plasma advanced glycation end-products and soluble receptor for advanced glycation end-products and mortality in colorectal cancer patients.
000292074 260__ $$aBognor Regis$$bWiley-Liss$$c2024
000292074 3367_ $$2DRIVER$$aarticle
000292074 3367_ $$2DataCite$$aOutput Types/Journal article
000292074 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1730278867_22133
000292074 3367_ $$2BibTeX$$aARTICLE
000292074 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000292074 3367_ $$00$$2EndNote$$aJournal Article
000292074 500__ $$a2024 Dec 1;155(11):1982-1995
000292074 520__ $$aAdvanced glycation end-products (AGEs), formed endogenously or obtained exogenously from diet, may contribute to chronic inflammation, intracellular signaling alterations, and pathogenesis of several chronic diseases including colorectal cancer (CRC). However, the role of AGEs in CRC survival is less known. The associations of pre-diagnostic circulating AGEs and their soluble receptor (sRAGE) with CRC-specific and overall mortality were estimated using multivariable-adjusted Cox proportional hazards regression among 1369 CRC cases in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Concentrations of major plasma AGEs, Nε-[carboxy-methyl]lysine (CML), Nε-[carboxy-ethyl]lysine (CEL) and Nδ-[5-hydro-5-methyl-4-imidazolon-2-yl]-ornithine (MG-H1), were measured using ultra-performance liquid chromatography mass-spectrometry. sRAGE was assessed by enzyme-linked immunosorbent assay. Over a mean follow-up period of 96 months, 693 deaths occurred of which 541 were due to CRC. Individual and combined AGEs were not statistically significantly associated with CRC-specific or overall mortality. However, there was a possible interaction by sex for CEL (Pinteraction = .05). Participants with higher sRAGE had a higher risk of dying from CRC (HRQ5vs.Q1 = 1.67, 95% CI: 1.21-2.30, Ptrend = .02) or any cause (HRQ5vs.Q1 = 1.38, 95% CI: 1.05-1.83, Ptrend = .09). These associations tended to be stronger among cases with diabetes (Pinteraction = .03) and pre-diabetes (Pinteraction <.01) before CRC diagnosis. Pre-diagnostic AGEs were not associated with CRC-specific and overall mortality in individuals with CRC. However, a positive association was observed for sRAGE. Our findings may stimulate further research on the role of AGEs and sRAGE in survival among cancer patients with special emphasis on potential effect modifications by sex and diabetes.
000292074 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000292074 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000292074 650_7 $$2Other$$aadvanced glycation end‐products (AGEs)
000292074 650_7 $$2Other$$acolorectal cancer
000292074 650_7 $$2Other$$amortality
000292074 650_7 $$2Other$$asoluble receptor of AGEs (sRAGE)
000292074 7001_ $$aRoshelli Baker, Jacqueline$$b1
000292074 7001_ $$00000-0002-0442-3284$$aAglago, Elom K$$b2
000292074 7001_ $$aZhao, Zhiwei$$b3
000292074 7001_ $$00000-0002-0237-0262$$aJiao, Li$$b4
000292074 7001_ $$00000-0001-8648-4998$$aFreisling, Heinz$$b5
000292074 7001_ $$aHughes, David J$$b6
000292074 7001_ $$aEriksen, Anne Kirstine$$b7
000292074 7001_ $$aTjønneland, Anne$$b8
000292074 7001_ $$00000-0001-7157-419X$$aSeveri, Gianluca$$b9
000292074 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b10$$udkfz
000292074 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b11$$udkfz
000292074 7001_ $$aSchulze, Matthias B$$b12
000292074 7001_ $$aMasala, Giovanna$$b13
000292074 7001_ $$00000-0001-5438-970X$$aPala, Valeria$$b14
000292074 7001_ $$aPasanisi, Fabrizio$$b15
000292074 7001_ $$aTumino, Rosario$$b16
000292074 7001_ $$aPadroni, Lisa$$b17
000292074 7001_ $$aVermeulen, Roel C H$$b18
000292074 7001_ $$00000-0002-0031-4152$$aGram, Inger T$$b19
000292074 7001_ $$aBraaten, Tonje$$b20
000292074 7001_ $$aJakszyn, Paula Gabriela$$b21
000292074 7001_ $$aSánchez, Maria-José$$b22
000292074 7001_ $$aGómez-Gómez, Jesús-Humberto$$b23
000292074 7001_ $$aMoreno-Iribas, Conchi$$b24
000292074 7001_ $$aAmiano, Pilar$$b25
000292074 7001_ $$aPapier, Keren$$b26
000292074 7001_ $$00000-0003-2237-0128$$aWeiderpass, Elisabete$$b27
000292074 7001_ $$aHuybrechts, Inge$$b28
000292074 7001_ $$00000-0001-6517-1300$$aHeath, Alicia K$$b29
000292074 7001_ $$aSchalkwijk, Casper$$b30
000292074 7001_ $$00000-0002-0573-1852$$aJenab, Mazda$$b31
000292074 7001_ $$00000-0002-7805-9913$$aFedirko, Veronika$$b32
000292074 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.35114$$gp. ijc.35114$$n11$$p1982-1995$$tInternational journal of cancer$$v155$$x0020-7136$$y2024
000292074 8564_ $$uhttps://inrepo02.dkfz.de/record/292074/files/Intl%20Journal%20of%20Cancer%20-%202024%20-%20Li%20-%20Pre%E2%80%90diagnostic%20plasma%20advanced%20glycation%20end%E2%80%90products%20and%20soluble%20receptor%20for.pdf
000292074 8564_ $$uhttps://inrepo02.dkfz.de/record/292074/files/Intl%20Journal%20of%20Cancer%20-%202024%20-%20Li%20-%20Pre%E2%80%90diagnostic%20plasma%20advanced%20glycation%20end%E2%80%90products%20and%20soluble%20receptor%20for.pdf?subformat=pdfa$$xpdfa
000292074 909CO $$ooai:inrepo02.dkfz.de:292074$$pVDB
000292074 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000292074 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000292074 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000292074 9141_ $$y2024
000292074 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000292074 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-21$$wger
000292074 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000292074 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000292074 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000292074 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000292074 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000292074 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000292074 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000292074 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000292074 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000292074 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2023-10-21
000292074 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2023-10-21
000292074 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000292074 980__ $$ajournal
000292074 980__ $$aVDB
000292074 980__ $$aI:(DE-He78)C020-20160331
000292074 980__ $$aUNRESTRICTED